Mikel Gurrea Rubio
Research Fellow
Internal Medicine
Department of Internal Medicine, Division of Rheumatology
109 Zina Pitcher PI, Room 4388
Ann Arbor, Michigan 48109
[email protected]

Available to mentor
Mikel Gurrea Rubio
Research Investigator
  • Qualifications
  • Recent Publications
    • Qualifications
    • Ph.D., Genetics
      University of Navarra, Pamplona, 2012
    • B.S., Biology
      University of Navarra, Pamplona, 2007
    • B.S., Biochemistry
      University of Navarra, Pamplona, 2007
    Recent Publications See All Publications
    • Journal Article
      Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways.
      Gurrea-Rubio M, Wang Q, Mills EA, Wu Q, Pitt D, Tsou P-S, Fox DA, Mao-Draayer Y. Int J Mol Sci, 2024 Feb 20; 25 (5): DOI:10.3390/ijms25052454
      PMID: 38473703
    • Journal Article
      Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells.
      Gurrea-Rubio M, Wu Q, Amin MA, Tsou P-S, Campbell PL, Amarista CI, Ikari Y, Brodie WD, Mattichak MN, Muraoka S, Randon PM, Lind ME, Ruth JH, Mao-Draayer Y, Ding S, Shen X, Cooney LA, Lin F, Fox DA. Cancer Immunol Immunother, 2024 Jan 27; 73 (2): 34 DOI:10.1007/s00262-023-03578-1
      PMID: 38280067
    • Journal Article
      Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis.
      Fox DA, Lundy SK, Whitfield ML, Berrocal V, Campbell P, Rasmussen S, Ohara R, Stinson A, Gurrea-Rubio M, Wiewiora E, Spino C, Bush E, Furst D, Pillai S, Khanna D. Arthritis Res Ther, 2021 Jan 6; 23 (1): 10 DOI:10.1186/s13075-020-02383-w
      PMID: 33407866
    • Journal Article
      Correction to: Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis.
      Fox DA, Lundy SK, Whitfield ML, Berrocal V, Campbell P, Rasmussen S, Ohara R, Stinson A, Gurrea-Rubio M, Wiewiora E, Spino C, Bush E, Furst D, Pillai S, Khanna D. Arthritis Res Ther, 2021 Mar 4; 23 (1): 73 DOI:10.1186/s13075-021-02459-1
      PMID: 33663570
    • Journal Article
      CD6 is a target for cancer immunotherapy.
      Ruth JH, Gurrea-Rubio M, Athukorala KS, Rasmussen SM, Weber DP, Randon PM, Gedert RJ, Lind ME, Amin MA, Campbell PL, Tsou P-S, Mao-Draayer Y, Wu Q, Lanigan TM, Keshamouni VG, Singer NG, Lin F, Fox DA. JCI Insight, 2021 Mar 8; 6 (5): DOI:10.1172/jci.insight.145662
      PMID: 33497367
    • Presentation
      CD6 is a target for autoimmunity and cancer immunotherapy
      Gurrea Rubio M. 2021 Feb;
    • Presentation
      Immunotherapy and suppression of autoimmunity with anti-CD6
      Gurrea Rubio M. 2021 Feb;
    • Presentation
      Multifaceted effect of soluble human CD6 in experimental cancer models
      Gurrea Rubio M. 2020 Jun;